Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider William Banyai sold 327 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $10,705.98. Following the completion of the sale, the insider now owns 345,986 shares in the company, valued at $11,327,581.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Twist Bioscience Trading Down 4.1 %
NASDAQ:TWST opened at $31.98 on Friday. Twist Bioscience Co. has a 52-week low of $11.46 and a 52-week high of $43.21. The business's fifty day moving average is $36.45 and its 200 day moving average is $29.19.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The firm's revenue for the quarter was up 31.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.74) EPS. Research analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current year.
Wall Street Analyst Weigh In
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Several analysts have issued reports on the company. Scotiabank boosted their target price on Twist Bioscience from $30.00 to $43.00 and gave the company a "sector outperform" rating in a research note on Monday, February 5th. Barclays boosted their target price on Twist Bioscience from $30.00 to $45.00 and gave the company an "overweight" rating in a research note on Thursday, January 25th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a "neutral" rating to a "buy" rating and lifted their price target for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th.
Read Our Latest Research Report on TWST
Hedge Funds Weigh In On Twist Bioscience
A number of institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new position in Twist Bioscience in the 4th quarter worth about $976,000. Virtu Financial LLC bought a new position in Twist Bioscience in the 4th quarter worth about $526,000. GSA Capital Partners LLP bought a new position in shares of Twist Bioscience during the 4th quarter valued at about $1,590,000. Mercer Global Advisors Inc. ADV increased its position in shares of Twist Bioscience by 16.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 26,019 shares of the company's stock valued at $959,000 after purchasing an additional 3,719 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Twist Bioscience by 4.1% during the 4th quarter. Barclays PLC now owns 253,986 shares of the company's stock valued at $9,363,000 after purchasing an additional 10,097 shares during the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
